JPC
JAZZ icon

Jackson Park Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Jackson Park Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-6,000
Closed -$729K – 38
2016
Q3 		$729K Hold
6,000
– – 0.95% 37
2016
Q2 		$848K Hold
6,000
– – 1.16% 34
2016
Q1 		$783K Buy
+6,000
New +$747K 1.01% 32

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jackson Park Capital's JAZZ Position: Q4 2016 in Review

Jackson Park Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2016, closing a stake of 6,000 shares — an estimated $729K sold.

Jackson Park Capital first reported a position in JAZZ in Q1 2016 and held it in 3 quarters. The position peaked at $848K in Q2 2016. 296 funds tracked by Wall St. Rank hold JAZZ as of Q4 2016.

  • Jackson Park Capital reported no remaining Jazz Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Jackson Park Capital sold 6,000 Jazz Pharmaceuticals shares in Q4 2016, an estimated $729K.
  • Jackson Park Capital first reported a position in Jazz Pharmaceuticals in Q1 2016 and held it in 3 quarters.
  • Jackson Park Capital's Jazz Pharmaceuticals position peaked at $848K in Q2 2016.
  • 296 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2016.

Based on Jackson Park Capital's 13F filing for Q4 2016, filed 1 Feb 2017.